The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without cancer returning for patients with hormone responsive breast cancer that have had their cancer removed by surgery and have completed required chemotherapy or radiation.
The current standard treatment after chemotherapy for patients with hormone responsive breast cancer is hormone treatment alone. Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney cancer. It is considered investigational for breast cancer patients.
Find out more about this trial at the National Cancer Institute.